Treatment strategies for primary early‐stage sinonasal adenocarcinoma: A retrospective bi‐institutional case‐control study. Issue 5 (8th September 2015)
- Record Type:
- Journal Article
- Title:
- Treatment strategies for primary early‐stage sinonasal adenocarcinoma: A retrospective bi‐institutional case‐control study. Issue 5 (8th September 2015)
- Main Title:
- Treatment strategies for primary early‐stage sinonasal adenocarcinoma: A retrospective bi‐institutional case‐control study
- Authors:
- Turri‐Zanoni, Mario
Battaglia, Paolo
Lambertoni, Alessia
Giovannardi, Marta
Schreiber, Alberto
Volpi, Luca
Bolzoni‐Villaret, Andrea
Lombardi, Davide
Bignami, Maurizio
Magnoli, Francesca
Facco, Carla
Antognoni, Paolo
Nicolai, Piero
Castelnuovo, Paolo - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso24038-sec-0001" sec-type="section"> <title>Objective</title> <p>To investigate different treatment strategies for primary early‐stage (pT1‐T2) sinonasal adenocarcinomas.</p> </sec> <sec id="jso24038-sec-0002" sec-type="section"> <title>Methods</title> <p>Retrospective case‐control study. From 2000 to 2011, 61 cases were radically resected using an endoscopic endonasal approach. Surgery as a single treatment modality was adopted for 33 patients (study group) while it was followed by postoperative radiotherapy (poRT) in 28 patients (control group).</p> </sec> <sec id="jso24038-sec-0003" sec-type="section"> <title>Results</title> <p>Median follow‐up was 61 and 67 months for the study and control group respectively. Patients were stratified according to the pT classification and no statistically significant differences were found in terms of Overall (OS) and Recurrence‐free (RFS) survival. When analyzing the high‐grade tumors (47 cases), statistically significant differences were observed between the control and study groups both in terms of OS (90.5% ± 6.5% versus 57.6% ± 15.4%, <italic>P</italic> = 0.03) and RFS (92.3% ± 7.39% versus 80.2% ± 8.88%, <italic>P</italic> = 0.05). Using multivariate analysis, OS was independently determined by poRT (Hazard Ratio = 0.16; <italic>P</italic> = 0.03) thus confirming its protective role for high‐grade adenocarcinomas.</p><abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso24038-sec-0001" sec-type="section"> <title>Objective</title> <p>To investigate different treatment strategies for primary early‐stage (pT1‐T2) sinonasal adenocarcinomas.</p> </sec> <sec id="jso24038-sec-0002" sec-type="section"> <title>Methods</title> <p>Retrospective case‐control study. From 2000 to 2011, 61 cases were radically resected using an endoscopic endonasal approach. Surgery as a single treatment modality was adopted for 33 patients (study group) while it was followed by postoperative radiotherapy (poRT) in 28 patients (control group).</p> </sec> <sec id="jso24038-sec-0003" sec-type="section"> <title>Results</title> <p>Median follow‐up was 61 and 67 months for the study and control group respectively. Patients were stratified according to the pT classification and no statistically significant differences were found in terms of Overall (OS) and Recurrence‐free (RFS) survival. When analyzing the high‐grade tumors (47 cases), statistically significant differences were observed between the control and study groups both in terms of OS (90.5% ± 6.5% versus 57.6% ± 15.4%, <italic>P</italic> = 0.03) and RFS (92.3% ± 7.39% versus 80.2% ± 8.88%, <italic>P</italic> = 0.05). Using multivariate analysis, OS was independently determined by poRT (Hazard Ratio = 0.16; <italic>P</italic> = 0.03) thus confirming its protective role for high‐grade adenocarcinomas.</p> </sec> <sec id="jso24038-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Our preliminary results suggest that endoscopic endonasal surgery could be used as a single treatment modality for primary early‐stage low‐grade sinonasal adenocarcinoma, resected with negative margins. Surgery followed by poRT offers the best treatment strategy not only for advanced‐stage lesions but also for high‐grade adenocarcinomas, regardless of the stage of disease at presentation. <italic>J. Surg. Oncol. 2015; 112:561–567</italic>. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Journal of surgical oncology. Volume 112:Issue 5(2015:Oct. 01)
- Journal:
- Journal of surgical oncology
- Issue:
- Volume 112:Issue 5(2015:Oct. 01)
- Issue Display:
- Volume 112, Issue 5 (2015)
- Year:
- 2015
- Volume:
- 112
- Issue:
- 5
- Issue Sort Value:
- 2015-0112-0005-0000
- Page Start:
- 561
- Page End:
- 567
- Publication Date:
- 2015-09-08
- Subjects:
- Cancer -- Surgery -- Periodicals
Neoplasms -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9098 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jso.24038 ↗
- Languages:
- English
- ISSNs:
- 0022-4790
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5067.380000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4233.xml